Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment.

The local immune response to influenza virus infection was characterized by determining cytokine and chemokine levels in serial nasal lavage fluid samples from 15 volunteers experimentally infected with influenza A/Texas/36/91 (H1N1). The study was part of a randomized double-blind placebo-controlled trial to determine the prophylactic effect of intravenous zanamivir (600 mg 2x/day for 5 days), a highly selective inhibitor of influenza A and B virus neuraminidases, on the clinical symptoms of influenza infection. Nasal lavage fluid levels of interleukin (IL)-6, tumor necrosis factor-alpha, interferon-gamma, IL-10, monocyte chemotactic protein-1, and macrophage inflammatory protein-1alpha and -1beta increased in response to influenza virus infection and correlated statistically with the magnitude and time course of the symptoms. Treatment with zanamivir prevented the infection and abrogated the local cytokine and chemokine responses. These results reveal a complex interplay of cytokines and chemokines in the development of symptoms and resolution of influenza.

[1]  R. Garofalo,et al.  Cell-Specific Expression of RANTES, MCP-1, and MIP-1α by Lower Airway Epithelial Cells and Eosinophils Infected with Respiratory Syncytial Virus , 1998, Journal of Virology.

[2]  B. Moss,et al.  Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  T. Tumpey,et al.  Absence of Macrophage Inflammatory Protein-1α Prevents the Development of Blinding Herpes Stromal Keratitis , 1998, Journal of Virology.

[4]  B. Rollins,et al.  Abnormalities in Monocyte Recruitment and Cytokine Expression in Monocyte Chemoattractant Protein 1–deficient Mice , 1998, The Journal of experimental medicine.

[5]  A. Luster,et al.  Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.

[6]  F. Hayden,et al.  Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. , 1998, The Journal of clinical investigation.

[7]  S. McColl,et al.  EBV induces the production and release of IL-8 and macrophage inflammatory protein-1 alpha in human neutrophils. , 1997, Journal of immunology.

[8]  R. Bravo,et al.  Defects in Macrophage Recruitment and Host Defense in Mice Lacking the CCR2 Chemokine Receptor , 1997, The Journal of experimental medicine.

[9]  Robert V Farese,et al.  Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. , 1997, The Journal of clinical investigation.

[10]  G. McFadden,et al.  Secreted poxvirus chemokine binding proteins , 1997, Journal of leukocyte biology.

[11]  I. Campbell,et al.  Chemokine gene expression in the brains of mice with lymphocytic choriomeningitis , 1997, Journal of virology.

[12]  Leming,et al.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections , 1997 .

[13]  T. Schwartz,et al.  A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. , 1997, Science.

[14]  R. Strieter,et al.  C-C chemokines differentially alter interleukin-4 production from lymphocytes. , 1997, The American journal of pathology.

[15]  R. Hromas,et al.  Functional characterization of the C---C chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Adachi,et al.  Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A. , 1996, The Journal of allergy and clinical immunology.

[17]  A. Lazzarin,et al.  Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. , 1996, The Journal of infectious diseases.

[18]  D. Gemsa,et al.  Selective induction of monocyte and not neutrophil-attracting chemokines after influenza A virus infection , 1996, The Journal of experimental medicine.

[19]  J. Friedland.  Chemokines in viral disease. , 1996, Research in virology.

[20]  F. Hayden,et al.  Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. , 1996, JAMA.

[21]  J. Sheridan,et al.  Requirement of MIP-1 alpha for an inflammatory response to viral infection. , 1995, Science.

[22]  F. Hayden,et al.  Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans , 1994, Antimicrobial Agents and Chemotherapy.

[23]  B. Dewald,et al.  Interleukin-8 and related chemotactic cytokines--CXC and CC chemokines. , 1994, Advances in immunology.

[24]  M. Graham,et al.  Response to influenza infection in mice with a targeted disruption in the interferon gamma gene , 1993, The Journal of experimental medicine.

[25]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[26]  F. Hayden,et al.  Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection , 1982, Antimicrobial Agents and Chemotherapy.